Currently, Denali Therapeutics Inc [DNLI] is trading at $27.78, up 6.23%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The DNLI shares have gain 5.31% over the last week, with a monthly amount drifted -5.61%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Cantor Fitzgerald downgraded its rating to Neutral on October 07, 2024. On December 13, 2023, Citigroup initiated with a Buy rating and assigned a price target of $32 on the stock. B. Riley Securities started tracking with a Buy rating for this stock on September 06, 2023, and assigned it a price target of $38. In a note dated January 30, 2023, SVB Securities initiated an Outperform rating and provided a target price of $50 on this stock.
This stock has fluctuated between a low of $14.56 and a high of $32.13 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $39.17 within the next 12 months. Denali Therapeutics Inc [NASDAQ: DNLI] shares were valued at $27.78 at the most recent close of the market. An investor can expect a potential return of 41.0% based on the average DNLI price forecast.
Analyzing the DNLI fundamentals
Trailing Twelve Months sales for Denali Therapeutics Inc [NASDAQ:DNLI] were 1.27M which represents -100.00% decline. Gross Profit Margin for this corporation currently stands at 1.03% with Operating Profit Margin at 1.63%, Pretax Profit Margin comes in at 1.38%, and Net Profit Margin reading is 1.38%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.34 and Total Capital is -0.35. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 26.74 points at the first support level, and at 25.70 for the second support level. However, for the 1st resistance point, the stock is sitting at 28.31, and for the 2nd resistance point, it is at 28.84.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Denali Therapeutics Inc [NASDAQ:DNLI] is 12.46. Also, the Quick Ratio is 12.46, while the Cash Ratio stands at 1.0. Considering the valuation of this stock, the price to sales ratio is 3131.48, the price to book ratio is 2.87.
Transactions by insiders
Recent insider trading involved Watts Ryan J., President and CEO, that happened on Oct 18 ’24 when 40000.0 shares were sold. Director, RYAN WATTS completed a deal on Oct 18 ’24 to buy 40000.0 shares. Meanwhile, Director Krognes Steve E. sold 30000.0 shares on Sep 30 ’24.
